According to Palatin Technologies's latest financial reports and stock price the company's current Operating Margin is -2,465.05%. At the end of 2022 the company had an Operating Margin of -2,465.06%.
Year | Operating Margin | Change |
---|---|---|
2022 | -2,465.06% | -86.16% |
2021 | -17,813.91% | -6.28% |
2020 | -19,006.88% | -32138.77% |
2019 | 59.32% | 60.69% |
2018 | 36.92% | -228.68% |
2017 | -28.69% | |
2015 | -140.50% | |
2013 | -218,274.12% | 778.46% |
2012 | -24,847.31% | 2625.06% |
2011 | -911.81% | 4532.92% |
2010 | -19.68% | -65.86% |
2009 | -57.64% | -57.77% |
2008 | -136.51% | -31.07% |
2007 | -198.05% | 32.02% |
2006 | -150.01% | 80.33% |
2005 | -83.19% | -92.75% |
2004 | -1,147.17% | -29.99% |
2003 | -1,638.59% | -72.11% |
2002 | -5,875.49% | 894.57% |
2001 | -590.76% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 22.88% | -100.93% | ๐บ๐ธ USA |
AstraZeneca AZN | 5.63% | -100.23% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | 14.36% | -100.58% | ๐บ๐ธ USA |
MediciNova MNOV | -250.93% | -89.82% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | 17.06% | -100.69% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | -61.01% | -97.53% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | -9.64% | -99.61% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | -34,735.80% | 1,309.13% | ๐บ๐ธ USA |
Ardelyx ARDX | -104.48% | -95.76% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.